Additionally, results from the company’s Chinese partner, CTTQ, have demonstrated the enhanced potency of bosakitug in respiratory conditions, including asthma and CRSwNP. While Aclaris intends ...

As of March 31, 2025, the Company’s cash and cash equivalents amounted to €67.9 million, compared to €96.6 million as of December 31, 2024. The decrease of €28.7 million is primarily ...

该药物在中国也正在进行临床试验，Aclaris的区域合作伙伴齐鲁天清制药集团有限公司(CTTQ)正针对重度哮喘和慢性鼻窦炎伴鼻息肉(CRSwNP)进行研究。CTTQ目前正在推进这些适应症的3期试验和慢性阻塞性肺病(COPD)的2期试验。该公司负责发布和展示临床试验结果。

CTTQ is currently advancing Phase 3 trials for these conditions and a Phase 2 trial for chronic obstructive pulmonary disease (COPD). The company is responsible for releasing and presenting the ...

WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno ...

As of March 31, 2025, the Company's cash and cash equivalents amounted to €67.9 million, compared to €96.6 million as of December 31, 2024. The decrease of €28.7 million is primarily due to the net ...

New York City (New York, United States), May 23, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical ...